 | |
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C28H30N4O |
| Molar mass | 438.575 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
SB-277,011A is a drug which acts as a potent and selectivedopamineD3 receptorantagonist,[1] which is around 80–100 times selective for D3 over D2,[2] and lacks anypartial agonist activity.[3]
SB-277,011A is used in the study ofaddiction tostimulant drugs such asnicotine[4] andcocaine.[5][6] Where cocaine reduces the threshold for brain electrical self-stimulation in rats, an indication of cocaine'srewarding effects, SB-277,011A completely reverses this effect. It may thus be useful in the treatment of addiction to nicotine and cocaine,[7][8][9] and is also being investigated for potential uses in the treatment of other drug addictions, such as addiction toheroin[10] andalcohol.[11][12][13]
Another potential application for SB-277,011A is in the treatment ofschizophrenia,[14] and it may be particularly useful in treatingcomorbid patients who are both schizophrenic and addicted to drugs.[15] However it may worsen side effects such astardive dyskinesia in patients who are already prescribedantipsychotic drugs.[16]
